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Abstract
Introduction—Non-steroidal anti-inflammatory drugs (NSAIDs) have a well-established 
analgesic efficacy for inflammatory pain. These drugs exert their effect by inhibiting the enzyme 
cyclooxygenase (COX) and are commonly used for the management of pain following endodontic 
treatment. There are two distinct isoforms of COX: COX-1, which is constitutively expressed; and 
COX-2, which is primarily induced by inflammation. Previous studies have shown that functional 
human genetic variants of the COX-2 gene may explain individual variations in acute pain. The 
present study extends this work by examining the potential contribution of the two COX isoforms 
to pain after endodontic treatment.
Methods—Ninety-four patients treated by endodontic residents at the University of North 
Carolina School of Dentistry were enrolled into a prospective cohort study. Data on potential 
predictors of post-treatment pain was collected and all patients submitted saliva samples for 
genetic analysis. Non-surgical root canal therapy was performed and participants recorded pain 
levels for five days following.
Results—In this study, 63% of patients experienced at least mild pain after root canal therapy 
and 24% experienced moderate to severe pain. Presence of pretreatment pain was correlated with 
higher post-treatment pain (p=0.01). Elevated heart rate (p=0.02) and higher diastolic blood 
pressure (p=0.024) were also correlated with decreased post-treatment pain. Finally, we identified 
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genetic variants in COX-2 (haplotype composed of rs2383515 G, rs5277 G, rs5275 T, and 
rs2206593 A) associated with post-treatment pain following endodontic treatment (p= 0.025).
Conclusion—Understanding the genetic basis of pain following endodontic treatment will 
advance its prevention and management.
Keywords
Cyclooxygenase; COX-1; COX-2; single nucleotide polymorphism; postoperative pain; 
odontogenic
INTRODUCTION
The general population commonly associates root canal treatment with pain, and post-
treatment pain remains frequent sequelae of endodontic treatment. A systematic review of 
sixteen studies on pain following endodontic treatment found that the prevalence of at least 
mild pain ranged from 3% to 58% (1). Up to 20% of patients report moderate to severe post-
treatment pain with the greatest intensity of pain reported during the first 24 hours following 
treatment (2, 3). It is well established that high levels of preoperative pain are predictive of 
higher levels of discomfort both intra- and postoperatively after endodontic treatment (2, 4). 
While many studies have evaluated other factors that could potentially affect post-treatment 
pain, none have examined genetic variants associated with pain in this patient population. 
While inter-individual differences in the experience of pain have been noted by clinicians, 
the genetic basis for acute pain conditions such as post-treatment endodontic pain remains 
unknown. Animal studies indicate that genetic variations account for 28 to 76% of pain 
experience (5). Potential candidate genes for pain modulation include the two isoforms of 
cyclooxygenase. Cyclooxygenase-1 (COX-1; prostaglandin H synthase1; PTGS1) is the 
constitutively expressed main enzyme involved in the synthesis of prostaglandin H2 from 
arachidonic acid, which is the committed step in prostaglandin (PG) synthesis. 
Cyclooxygenase-2 (COX-2; prostaglandin H synthase2; PTGS2) is inducible and has a role 
primarily in the production of PGs that promote inflammation (6–8). In vivo studies on 
orofacial pain clearly show that COX-1 is expressed in normal (uninflamed) tissues while 
COX-2 is induced by inflammation in a time-dependent manner (9,10). Inhibition of 
cyclooxygenase isoforms by drugs such as aspirin and non-steroidal anti-inflammatory 
drugs (NSAIDs) results in decreased synthesis of PGs and decreased pain. Ibuprofen, the 
prototypical NSAID, is the drug of choice among endodontists for the management of post-
treatment pain (4).
Genetic variations of COX-1 and COX-2 have been explored in several studies on pain (10–
12). These studies suggest that functional polymorphisms in COX-2 may account, in part, 
for inter-individual variations in pain (10, 13). In addition, polymorphisms in COX-2 may 
also account for inter-individual differences in analgesic responses to NSAIDs and selective 
COX-2 inhibitors (10). However, the associations between COX-1 and COX-2 
polymorphisms and post-treatment pain in endodontic patients are yet to be explored.
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Thus, we conducted a prospective study to examine the contribution of COX-1 and COX-2 
genetic variants as well as phenotypic and physiological factors to the development of post-
treatment pain in endodontic patients.
MATERIALS AND METHODS
Study Participants
Patients were recruited from the University of North Carolina-Chapel Hill School of 
Dentistry Graduate endodontic clinic. The inclusion criteria were patients of age ≥18 years 
old and American Society of Anesthesiologists class I or II. Patients who were taking 
corticosteroid medications and those unable to take ibuprofen were excluded from the study. 
This study was approved by our Institutional Review Board and written informed consent 
was obtained from all study participants.
Patients were asked to complete questionnaires prior to treatment to establish baseline pain 
levels as well as tooth pain experienced in the last 24 hours using a Likert scale (with the 
anchors “No pain” and “Worst pain imaginable”). After completion of the pretreatment pain 
questionnaires the subjects resting arterial blood pressure and heart rate were measured once 
using a wrist cuff blood pressure monitor on the right arm. The monitor used was the 
OMRON Model HEM 605 (OMRON Vernon Hills, Illinois). These measurements were 
taken approximately 15 minutes after seating the patient in an upright position. Salivary 
DNA was collected prior to the initiation of root canal treatment using the Oragene Self-
Collection System (DNA Genotek, Ontario, Canada). This system yields high quality DNA, 
similar to that purified from blood. It is convenient, proven, and specimens remain intact for 
years in their collected media at room temperature.
While the protocol for root canal treatment was not standardized, the basic protocol used by 
UNC endodontic graduate students includes chemomechanical debridement by shaping the 
canals to a minimal apical size of 40.04 and irrigation with sodium hypochlorite and 
ethylenediaminetetraacetic acid. The root canal system was then either obturated with 
Resilon/Epiphany™ (SybroEndo Co., Orange, CA) or calcium-hydroxide powder mixed 
with 2% chlorhexidine was placed as an interappointment medicament, and the access was 
restored.
Study participants completed a pain diary for five consecutive days after treatment. The 
instructions were to complete the diary at bedtime and record the time of day and the worst 
pain they felt in the teeth or mouth during the past 24 hours on a Likert scale. While no 
medications were prescribed, patients were asked to report any analgesics, including dosage 
and frequency, which may have been self-administered during the postoperative period.
Genetic data was processed at Cogenics™ Genomics Services Company (Cary, NC). DNA 
was extracted from the saliva using the 4 ml Oragene DNA Purifier System and quantified 
using Pico Green Assay kit (Life Technologies, Grand Island, NY) to ensure DNA 
concentration of at least 10 ng/µl. SNP genotyping was performed using iPLEX Gold 
chemistry (Sequenom, San Diego, CA). SNP Assays were designed by MassARRAY Assay 
Design 3.1 (Sequenom, San Diego, CA). iPLEX Gold chemistry utilizes multiplex PCR. 
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After the PCR, remaining nucleotides are deactivated by Shrimp Alkaline Phosphatase 
(SAP) treatment. Then single base primer extension is performed, and the primer extension 
products are analyzed using MALDI TOF Mass Spectrometer. From the MALDI TOF Mass 
Spectrometer peak information we are able to accurately genotype the SNP of interest using 
Typer 4 software (Sequenom, San Diego, CA.) Samples that failed to amplify sufficiently 
for allelic discrimination were not included in the final analysis.
Statistical Analysis
Data were analyzed with R. software (version 2.8.1; 2008, Vienna, Austria) Linear 
regression was used to evaluate the association between postoperative pain and preoperative 
pain, heart rate, and blood pressure. The association between each genetic variable and 
postoperative pain was evaluated using ANOVA. Haplotypes (and associated posterior 
probabilities) were constructed for each participant using the EM algorithm (implemented in 
the “haplo.stats” R package) (14). All values are reported as mean ± standard error.
RESULTS
Patient Characteristics
This study enrolled 69 subjects (39 male and 30 female) aged 18–85 years for whom we 
obtained baseline data, post-operative data, and salivary DNA. Subject demographics and 
baseline characteristics are displayed in Table 1. Of the 69 subjects, 48 were self-identified 
as Caucasian, 7 as African-American, 7 as Hispanic, 6 as Asian, and 1 as other. Only 12 
subjects (17%) reported preoperative pain within the past 24 hours on the day of enrollment. 
Pulpal and periapical diagnoses varied across patients. Thirty-five (51%) subjects presented 
with a periapical radiolucency. There were no statistically significant differences between 
male and female subjects in any of the demographic characteristics measured. The majority 
of treated teeth (66%) were molars. An equal number of teeth were treated in the maxillary 
and mandibular arches.
The course of mean postoperative endodontic pain by gender is shown in Figure 2. No 
differences between males and females were observed in the worst pain intensity reported. 
As shown in Figure 3, 63% of subjects reported at least mild pain postoperatively. Reported 
mean worst pain intensity decreased gradually over the five-day period. Most subjects (88%) 
were pain-free by Day 5.
On day 1, 20 subjects (39%) reported taking oral analgesics for postoperative pain. On 
postoperative day 2, only 9 subjects (18%) reported taking pain medication and by 
postoperative day 5, only 2 subjects (4%) reported taking pain medication. All but 1 subject 
who used postoperative analgesics took NSAIDs (ibuprofen and naproxen).
Phenotypic Factors Associated with Post-treatment Pain Level
None of the demographic characteristics were found to be associated with mean Day 1 worst 
pain or average pain. The relationships between preoperative and postoperative pain are 
shown in Tables 2 and 3. Twenty-five subjects (59%) who did not experience pretreatment 
pain did experience at least mild postoperative pain on Day 1, while 7 (78%) subjects who 
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experienced preoperative pain also experienced postoperative pain. Specifically, 
preoperative pain was associated with higher intensity of reported mean Day 1 worst pain 
level (p = 0.017; R2 = 0.10).
Physiologic Factors Associated with Post-treatment Pain Level
Alterations in heart rate and blood pressure were linked to postoperative pain, such that 
higher resting heart rate (p = 0.020) and diastolic arterial blood pressure (p = 0.024) were 
associated with lower mean Day 1 average pain. Systolic arterial blood pressure was not 
significantly associated with postoperative pain on Day 1 (p = 0.21 and p = 0.15).
Genetic Variation and Post-treatment Pain Levels
The genotype frequencies of each tested SNP in COX-1 and COX-2 are shown in Table 4. 
The 4 COX-2 SNPs tested were in high linkage disequilibrium (D’ =0.99–1) and formed a 
haploblock composed of 1 SNP in the promoter region (rs2383515 G/T), 1 SNP in the 
coding region (rs5277 C/G), and 2 SNPs in the 3’ UTR (rs5275 C/T and rs2206593 A/G) 
(Table 5). The GGTA haplotype was associated with Day 1 worst pain postoperative. (p = 
0.025).
DISCUSSION
We employed a prospective cohort study to identify phenotypic, physiologic, and genetic 
factors that contribute to the incidence and intensity of postoperative pain following 
endodontic treatment. Among patients presenting to the UNC School of Dentistry for root 
canal treatment, the incidence and intensity of pain after nonsurgical root canal treatment 
reached its maximum within the first 24 hours of treatment, when 63% of patients reported 
pain (mean = 1.88 ± 0.28). Nearly 25% of patients reported Day 1 worst pain levels of more 
than four on a nine point Likert scale and 38% felt the need to control their postoperative 
pain symptoms with non-steroidal anti-inflammatory drugs (NSAIDs), with ibuprofen being 
the most frequently used. These findings are in line with those of other studies 
demonstrating that 68–70% of root canal treatments are associated with postoperative pain, 
with 17% reporting symptoms of severe nature (15,16). By day 3 after root canal treatment, 
the incidence of pain decreased to 30%. This estimate is higher than that of Genet and 
colleagues, showing very little pain 3 days posttreatment (17.
No differences were observed in pain levels in teeth with or without periapical radiolucency. 
This finding is in agreement with those of Harrison, Georgopoulou, and O’Keefe (2, 3,16), 
but not with those of Marshall and Liesinger (18), who found that patients with no 
radiographic periapical lesions had significantly more pain than patients with lesions. The 
age and sex of the patient and dental arch treated appeared not to influence the incidence of 
pain; this is in accord with the results of Harrison, Georgopoulou, O’Keefe, and Albashaireh 
and Alnegrish (2, 3, 16,19).
Consistent with previous studies (3, 4,17), we found a strong association between 
preoperative pain and postoperative pain. Specifically, the intensity of preoperative pain was 
correlated with more severe pain on postoperative Day 1 ((p = 0.017). Furthermore, we 
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found that 10% of worst pain on postoperative Day 1 could be explained by the presence or 
absence of pretreatment pain (R2 = 0.10).
We also found associations between physiologic measures and post-operative pain, such that 
lower resting heart rate and lower diastolic arterial blood pressure were associated with 
higher mean Day 1 average. That higher resting blood pressure is associated with decreased 
pain sensitivity is well-established (20,21). Specifically, normal pain-free subjects with 
higher blood pressures at rest have a higher pain threshold and tolerance compared with 
subjects with lower blood pressures (20). King et al. observed significant correlations 
between preoperative systolic blood pressure and postoperative pain after non-surgical root 
canal treatment (2). The exact mechanism for the contribution of arterial blood pressure to 
experimental pain sensitivity remains unknown. One proposed mechanism involves 
activation of the carotid sinus baroreceptors (23).
Finally, we explored the association between COX-1 and COX-2 genetic variants and 
postoperative pain. While our results are tentative due to a small sample size, they show that 
in COX-2, a haplotype composed of rs2383515 G, rs5277 G, rs5275 T, and rs2206593 A 
was associated with worst pain scores on postoperative Day 1. Little is known about a 
genetic association between the COX-2 SNPs we identified in this study and acute pain. The 
rs5277 polymorphism of COX-2 has been identified as a potential modifier of breast cancer 
risk (4) and pancreatic cancer susceptibility (25), though it is not currently considered a risk 
factor. The rs5275 SNP in the COX-2 3’UTR has potential miRNA-binding sites in 
lymphoblastoic cell lines (26) and has been associated with a reduced risk of premalignant 
lesions in the oral cavity (27). Currently, no literature exists discussing the role of rs2383515 
and rs2206593 in pain or inflammatory processes.
Our data on COX-1 show a trend towards an association between rs1236913 SNP and worst 
pain scores on postoperative Day 1. This SNP is located in exon 2, produces a 
nonsynonymous change in amino acid from tryptophan to arginine at codon 102 (28,29), and 
is associated with the severity of ankylosing spondylitis, a chronic inflammatory disease of 
the axial skeleton (30).
While these results suggest that specific COX-1 and COX-2 genetic variants may be useful 
to predict patient risk of postoperative pain and benefit of drugs, further studies are required 
to replicate associations between COX genetic variants and postoperative pain in a larger 
population of endodontic patients as well as to evaluate potential functional changes in the 
expression of corresponding COX and downstream PG proteins. Understanding acute pain 
conditions on a genetic level has important implications for their future management. 
NSAIDs that target COX-1 and COX-2 are the frontline treatment for post-treatment pain in 
endodontics. The discovery of functional polymorphisms in the COX genes may ultimately 
improve the safe and effective use of NSAIDS by better tailoring drug dosage in accordance 
with an individual’s genetic variation.
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Tested SNP locations on COX-1 (rs1236913; rs3842803; rs10306202; rs5789; rs10306114; 
rs1213266; rs3842788) on chromosome 9 and COX-2 (rs2206593; rs2383515; rs5275; 
rs5277) on chromosome 1.
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Postoperative pain among (A) all patients and (B) patients experiencing pain after 
endodontic treatment. Patients recorded their worst pain intensity in a daily pain diary using 
a Likert scale with the anchors “No pain” and “Worst pain imaginable.
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Incidence of post-operative pain. Endodontic patients recorded their odontogenic pain in a 
pain diary for five consecutive days after treatment.
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Table 1








Total Enrolled 39 (57) 30 (43) 69
Average Age (years) 54 ± 3.02 42 ± 2.80 48 ± 2.19
Racial Distribution*
White 27 (69) 21 (70) 48 (70)
Black 4 (10) 3 (10) 7 (10)
Hispanic 5 (13) 2 (7) 7 (10)
Asian 2 (5) 4 (13) 6 (9)
Other 1 (3) 0 (0) 1 (1)
Subjects with Pretreatment Pain 6 (15) 6 (20) 12 (17)
Subjects without Pretreatment Pain 33 (85) 24 (80) 57 (83)
Presence of Periapical Disease 25 (64) 17 (57) 42 (61)
Presence of Periapical Radiolucency 22 (56) 13 (43) 35 (51)
*
Values are expressed as number (percentage) unless otherwise indicated
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Table 2
Postoperative Pain Course in Patients Experiencing Pain
Males Females Overall
Day 1
Worst pain level** 2.67 (0.42) 3.19 (0.50) 2.91 (0.32)
Average pain level 1.81 (0.29) 2.43 (0.36) 2.10 (0.23)
Day 2
Worst pain level 2.03 (0.34) 2.55 (0.50) 2.23 (0.28)
Average pain level 1.36 (0.17) 2.22 (0.49) 1.70 (0.23)
Day 3
Worst pain level 2.00 (0.60) 3.43 (0.90) 2.59 (0.52)
Average pain level 1.86 (0.59) 2.29 (0.57) 2.07 (0.40)
Day 4
Worst pain level 2.67 (1.31) 2.60 (0.93) 2.64 (0.79)
Average pain level 3.33 (1.86) 2.20 (0.73) 2.63 (0.78)
Day 5
Worst pain level 1.33 (0.33) 3.00 (2.00) 2.17 (0.98)
Average pain level 1.00 (NA) 2.67 (1.67) 2.25 (1.25)
*
Value expressed as N Subjects/Total N (percentage)
**
Values are expressed as mean score % (standard error of the mean) unless otherwise indicated; Pain was expressed on a 9-point Likert scale with 
anchors 0 (No Pain) to 9 (Worst pain imaginable)
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Table 3
Post-Operative Pain in Study Subjects Presenting with or without Preoperative Pain
Subjects Presenting without
Preoperative Pain
Subjects Presenting with Preoperative
Pain
N (%) N (%)
Males 14 (58) 3 (60)
Females 11(61) 4(100)
Overall 25(59) 7 (78)
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